Lilly Gets Hooked on AI Drugs Courtesy of Insilico ($2.75B Check Loading)
“Yeah, science, b*tch!” - Jesse Pinkman Insilico Medicine
Twenty seven days. That’s how long Eli Lilly CEO David Ricks lasted between telling Fortune that AI is "not particularly good" at solving biology… and writing a $2.75 billion check to an AI drug company. (The man's conviction aged like milk).
In short, Lilly's new plug (read: Insilico Medicine) is getting $115 million upfront for exclusive rights to an AI-discovered GLP-1 drug for diabetes, with up to $2.63 billion more tied to regulatory and sales milestones. Plus royalties. Mr. Wonderful walked so Insilico could run.
That said, who the actual hell is Insilico? Good question. The company was founded in 2014 at John Hopkins… before OpenAI, before Anthropic, before your favorite chatbot learned to hallucinate. Since then, they’ve Walter White’d (read: cooked up) 28+ drugs using generative AI, nearly half already in clinical trials. IPO'd in Hong Kong in December, with shares popping 10% over the last five days.
Oh, and in the Spirit of Russ Hanneman… they’re unprofitable. Fun fact: Lilly's Asian venture arm is already one of Insilico's 10 largest shareholders. So the trillion-dollar pharma giant is buying drugs from a company it partially owns… that doesn't make money. Translation: Eli Lilly knows how to get its John Paul Getty on.
But alas, keep in mind, this is Lilly’s FOURTH AI deal this quarter. Innovent Biologics: $350 million upfront, $8 billion potential. Excalipoint: invested. XtalPi: $345 million. Plus a $3 billion pledge to China manufacturing over the next decade. All while generating less than 3% of revenue from China. (3% of the revenue, 100% of the shopping budget.)
Additionally, a record $5.6 billion in Chinese drug licensing went to foreign pharma in 2025. So the whole industry is hooked, but Lilly is absolutely the one bringing the most cash to the dealer's door. Of course, there's a reason for the full-send. Mounjaro was the world's second-biggest drug by sales in 2025, and Novo Nordisk has been coming for the crown. They beat Lilly to the first approved weight-loss pill, Wegovy HD just got FDA approval, and Lilly's stock is down 17% in 2026. But then again… Novo is down -30% YTD, so there’s that.
Now obviously, we’ll see what comes of it. Maybe nothing, maybe something. But regardless, Insilico’s apparently been cooking since 2014 while everyone else was still reading the recipe. Now Big Pharma's showed up with the bag… and can't stop coming back for more. Place your bets accordingly, friends. Until next time…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.